Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.04
-3.6%
$1.85
$1.43
$4.26
$204.84M1.62143,202 shs64,981 shs
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$65.04
-1.6%
$63.47
$52.50
$77.00
$1.41B0.57315,301 shs129,038 shs
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$18.73
+2.8%
$15.56
$7.75
$19.93
$142.68M0.6227,849 shs24,624 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+1.44%+2.43%-4.09%+35.26%-38.84%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+1.21%+1.24%+5.14%-2.97%+5.96%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-2.67%+0.39%+5.62%+100.66%+31.74%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune stock logo
ACIU
AC Immune
2.943 of 5 stars
3.53.00.00.03.70.80.6
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.7365 of 5 stars
2.51.00.03.31.93.31.3
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.7979 of 5 stars
3.33.00.04.72.40.00.0
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
3.00
Buy$12.00489.68% Upside
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8821.27% Upside
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0076.19% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACIU, ASMB, NBRV, ANIP, and ZIOP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$84.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/1/2025
AC Immune stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
4/21/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$62.00 ➝ $65.00
4/11/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$31.02M6.59N/AN/A$1.29 per share1.58
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$674.07M2.09$7.56 per share8.60$19.11 per share3.40
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$32.15M4.45N/AN/A$5.25 per share3.57
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.45N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ACIU, ASMB, NBRV, ANIP, and ZIOP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
AC Immune stock logo
ACIU
AC Immune
-$0.18N/AN/AN/A$1.98 millionN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
4/30/2025Q1 2025
AC Immune stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.53
1.53
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.23 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

Recent News About These Companies

Best Global Universities for Oncology
FDA fast-tracks Merck's cancer blockbuster-in-waiting
Childhood Cancers
Alx Oncology Holdings (ALXO)
Pediatric Hematology-Oncology Fellowship
CG Oncology Inc
Immuno-Oncology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Association of Community Cancer Centers
Oncology News and Research
WBSPH 2024 - Oncology
Kris on Oncology
Oncology Cases & Quizzes

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.05 -0.06 (-2.80%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$64.92 -1.18 (-1.79%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$18.71 +0.49 (+2.71%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

ZIOPHARM Oncology stock logo

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.